Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Epigenetic drug discovery: targeting DNA methyltransferases.

Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M, Wright K, Hendrickson TF, Ho KK, McCullar MV, Kanner SB.

J Biomol Screen. 2012 Jan;17(1):2-17. doi: 10.1177/1087057111421212. Epub 2011 Sep 30. Review. Erratum in: J Biomol Screen. 2012 Jun;17(5):700.

PMID:
21965114
2.

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.

Fahy J, Jeltsch A, Arimondo PB.

Expert Opin Ther Pat. 2012 Dec;22(12):1427-42. doi: 10.1517/13543776.2012.729579. Epub 2012 Oct 3. Review.

PMID:
23033952
3.
4.

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

Stresemann C, Lyko F.

Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607. Review.

6.

DNA hypermethylation as a chemotherapy target.

Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, Hwa YL, Li J, Dowdy SC, Jiang SW.

Cell Signal. 2011 Jul;23(7):1082-93. doi: 10.1016/j.cellsig.2011.02.003. Epub 2011 Feb 21. Review.

PMID:
21345368
8.

Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.

Rubinstein JC, Tran N, Ma S, Halaban R, Krauthammer M.

BMC Med Genomics. 2010 Feb 9;3:4. doi: 10.1186/1755-8794-3-4.

9.

Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.

Eglen RM, Reisine T.

J Biomol Screen. 2011 Dec;16(10):1137-52. doi: 10.1177/1087057111417871. Epub 2011 Oct 14. Review.

PMID:
22002420
10.

Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.

Cowan LA, Talwar S, Yang AS.

Epigenomics. 2010 Feb;2(1):71-86. doi: 10.2217/epi.09.44. Review.

PMID:
22122748
11.

DNA methyltransferase inhibitors for cancer therapy.

Brueckner B, Kuck D, Lyko F.

Cancer J. 2007 Jan-Feb;13(1):17-22. Review.

PMID:
17464242
12.

DNA methylation and gene silencing in cancer.

Baylin SB.

Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11. Review.

PMID:
16341240
13.

Novel approaches on epigenetics.

Papait R, Monti E, Bonapace IM.

Curr Opin Drug Discov Devel. 2009 Mar;12(2):264-75. Review.

PMID:
19333872
14.

TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.

Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP, Matei D.

Epigenetics. 2014 Nov;9(11):1461-72. doi: 10.4161/15592294.2014.971608.

15.

Clinical advances in hypomethylating agents targeting epigenetic pathways.

Cang S, Lu Q, Ma Y, Liu D.

Curr Cancer Drug Targets. 2010 Aug;10(5):539-45. Review.

PMID:
20384584
16.

DNA methyltransferase inhibitors: an updated patent review (2012-2015).

Xu P, Hu G, Luo C, Liang Z.

Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. doi: 10.1080/13543776.2016.1209488. Epub 2016 Jul 18. Review.

PMID:
27376512
17.

Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?

Lowder JN, Taverna P, Issa JP.

Epigenomics. 2015 Oct;7(7):1083-8. doi: 10.2217/epi.15.66. Epub 2015 Nov 6. No abstract available.

PMID:
26541345
18.

Targeting DNA methylation for epigenetic therapy.

Yang X, Lay F, Han H, Jones PA.

Trends Pharmacol Sci. 2010 Nov;31(11):536-46. doi: 10.1016/j.tips.2010.08.001. Epub 2010 Sep 16. Review.

19.

Targeting DNA methylation with small molecules: what's next?

Erdmann A, Halby L, Fahy J, Arimondo PB.

J Med Chem. 2015 Mar 26;58(6):2569-83. doi: 10.1021/jm500843d. Epub 2014 Dec 4. Review.

PMID:
25406944
20.

Epigenetic-based therapies in cancer: progress to date.

Song SH, Han SW, Bang YJ.

Drugs. 2011 Dec 24;71(18):2391-403. doi: 10.2165/11596690-000000000-00000. Review.

PMID:
22141383

Supplemental Content

Support Center